510(K) SUMMARY

SUBMITTER INFORMATION

A. Company Name: IntraLuminal Therapeutics, Inc.

B. Company Address: 6354 Corte Del Abeto - Suite A

Carlsbad, CA 92009

C. Company Phone: (760) 918-1820

D. Company Facsimile: (760) 603-9615

E. Contact Person: Pamela Misajon

Vice President of Regulatory Affairs and Quality Assurance

DEVICE IDENTIFICATION

A. Device Trade Name: Safe-Cross Radio Frequency Total Occlusion

Crossing System

B. Device Common Name: Guidewire

D. Classification Name: Catheter Guidewire

E. Device Class: Class II (per 21 CFR 870.1330)

IDENTIFICATION OF PREDICATE DEVICE

The predicate device is the Safe-Steer[™] Guide Wire System, manufactured by Intraluminal Therapeutics and cleared under 510(k) Premarket Notification number K021323.

DEVICE DESCRIPTION

The Safe-CrossTM Radio Frequency (RF) Total Occlusion (TO) Crossing System consists of a the following:

- 0.014" Safe-Cross RF Crossing Wire Straight and Angled Tip (with Torquer)
- Safe-Steer™ Optical Coherence Reflectometry (OCR) Unit with Display Monitor
- Safe-Cross RF Generator with Footswitch and Interface Cable

The Safe-Cross RF Crossing Wire is similar to the predicate guidewire in construction and intended use. The proximal end of the Crossing Wire is connected to a Y-Site hub



that houses the optic fiber connector and the RF connector. The optical connector is connected to the OCR Unit to allow the medical practitioner to visualize structures within the vessel for navigation purposes. The RF connector is connected to the RF Generator. This allows the medical practitioner to provide discrete RF energy to the distal tip to assist in moving the wire tip through the occlusion in the vessel.

The RF Crossing Wire is packaged in a Tyvek® sealed plastic tray. The packaged RF Crossing Wire is sterilized by ethylene oxide gas. The packaged RF Crossing Wire is provided "STERILE" and Non-pyrogenic, and is intended for single use only.

INTENDED USE

The Safe-Cross® Radio Frequency Total Occlusion Crossing System is indicated for use in facilitating the placement of devices used in percutaneous interventions in native coronary arteries with total occlusions.

TECHNOLOGICAL CHARACTERISTICS

The components of the Safe-Cross System are similar in basic materials, design, construction and performance to the predicate device. The RF Generator is an additional component of the Safe-Cross System. The performance of the RF Generator has been verified through bench, animal, and human clinical studies.

BIOCOMPATIBILITY AND PERFORMANCE DATA

Biocompatibility testing, in vitro bench testing and in vivo animal studies were conducted to evaluate the biological and performance characteristics of the Safe-Cross System. Biocompatibility test results indicate that the patient contact components of the Safe-Cross Crossing Wire are biocompatible. Benchtop performance test results indicate that the components of the Safe-Cross System satisfy safety and performance requirements of the device specifications. In Vivo animal studies demonstrate that the various components of the Safe Cross System function together, as intended, in the animal model and do not raise unanticipated safety issues.

CLINICAL STUDIES

Human clinical studies have been conduct to verify the safety and performance characteristics of the Safe-Cross System when used in human subjects for the indicated use of crossing total occlusions in native coronary arteries. The results of the clinical studies indicate that the device performs as intended and does not involve unacceptable risk to the patient.

CONCLUSIONS DRAWN FROM STUDIES

The results of nonclinical and clinical testing demonstrate that Safe-Cross System is substantially equivalent to the predicate device and satisfies the requirements of the device specifications.

Confidential 107



JAN - 7 2004

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

IntraLuminal Therapeutics, Inc. c/o Ms. Pamela Misajon Vice President of Regulatory Affairs and Quality Assurance 6354 Corte Del Abeto – Suite A Carlsbad, CA 92009

Re:

K032031

Safe-Cross Radio Frequency Total Occlusion Crossing System

Regulation Number: 21 CFR 870.1330 Regulation Name: Catheter Guidewire

Regulatory Class: Class II Product Code: DQX Dated: October 10, 2003 Received: October 14, 2003

Dear Ms. Misajon:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Page 2 - Ms. Pamela Misajon

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4648. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address

http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Bram D. Zuckerman, M.D.

Director

Division of Cardiovascular Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

INDICATIONS FOR USE

510(k) Number:	To Be Assigned By FDA	K-632031
Device Name:	Safe-Cross® RF TO Cross	ing System
Indications For Use:	System is indicated for us	Frequency Total Occlusion Crossing e in facilitating the placement of devices ventions in native coronary arteries with
NEEDED		- CONTINUE ON ANOTHER PAGE IF
Concurrence of CDR	tH, Office of Device Evalua	tion (ODE)
المارية المراجع		
Prescription Use(Per 21 CFR 801.10	OR 9)	Over-The-Counter Use
(Division of Ca	rdiovascular Devices	•
510(K) Numb	F632031 SM. K	